Australija - anglų - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - alanine, quantity: 14 g/l; arginine, quantity: 12 g/l; glycine, quantity: 11 g/l; histidine, quantity: 3 g/l; isoleucine, quantity: 5 g/l; leucine, quantity: 7.4 g/l; lysine acetate, quantity: 9.31 g/l (equivalent: lysine, qty 6.6 g/l); methionine, quantity: 4.3 g/l; phenylalanine, quantity: 5.1 g/l; proline, quantity: 11.2 g/l; serine, quantity: 6.5 g/l; taurine, quantity: 1 g/l; threonine, quantity: 4.4 g/l; tryptophan, quantity: 2 g/l; tyrosine, quantity: 400 mg/l; valine, quantity: 6.2 g/l - injection, solution - excipient ingredients: glacial acetic acid; water for injections - to supply amino acids as part of a composite admixture of total parenteral nutrition.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - alanine, quantity: 14 g/l; arginine, quantity: 12 g/l; glycine, quantity: 11 g/l; histidine, quantity: 3 g/l; isoleucine, quantity: 5 g/l; leucine, quantity: 7.4 g/l; lysine acetate, quantity: 9.31 g/l (equivalent: lysine, qty 6.6 g/l); methionine, quantity: 4.3 g/l; phenylalanine, quantity: 5.1 g/l; proline, quantity: 11.2 g/l; serine, quantity: 6.5 g/l; taurine, quantity: 1 g/l; threonine, quantity: 4.4 g/l; tryptophan, quantity: 2 g/l; tyrosine, quantity: 400 mg/l; valine, quantity: 6.2 g/l - injection, solution - excipient ingredients: glacial acetic acid; water for injections - to supply amino acids as part of a composite admixture of total parenteral nutrition.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - threonine, quantity: 3.7 mg/ml; proline, quantity: 3 mg/ml; glycine, quantity: 4 mg/ml; arginine, quantity: 8.4 mg/ml; tyrosine, quantity: 0.45 mg/ml; valine, quantity: 7.6 mg/ml; leucine, quantity: 10 mg/ml; serine, quantity: 4 mg/ml; isoleucine, quantity: 6.7 mg/ml; cysteine, quantity: 1.89 mg/ml; taurine, quantity: 0.6 mg/ml; lysine, quantity: 11 mg/ml; ornithine monohydrochloride, quantity: 3.18 mg/ml; histidine, quantity: 3.8 mg/ml; alanine, quantity: 8 mg/ml; aspartic acid, quantity: 6 mg/ml; methionine, quantity: 2.4 mg/ml; glutamic acid, quantity: 10 mg/ml; tryptophan, quantity: 2 mg/ml; phenylalanine, quantity: 4.2 mg/ml - injection, intravenous infusion - excipient ingredients: malic acid; water for injections - primene 10% amino acid iv infusion is indicated in infants and neonates at term or premature, for short-term use, of normal or low birth-weight when oral or enteral nutrition is impossible, insufficient or contraindicated. it is used as an amino acid component in a composite admixture of total parenteral nutrition.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - acetate, quantity: 135 mmol/l; leucine, quantity: 5.9 g/l; valine, quantity: 5.5 g/l; arginine, quantity: 8.4 g/l; sulfate, quantity: 8 mmol/l; isoleucine, quantity: 4.2 g/l; calcium, quantity: 5 mmol/l; phenylalanine, quantity: 5.9 g/l; aspartic acid, quantity: 2.5 g/l; tyrosine, quantity: 0.17 g/l; tryptophan, quantity: 1.4 g/l; alanine, quantity: 12 g/l; chloride, quantity: 100 mmol/l; potassium, quantity: 50 mmol/l; glycine, quantity: 5.9 g/l; histidine, quantity: 5.1 g/l; threonine, quantity: 4.2 g/l; - injection, intravenous infusion - excipient ingredients: water for injections - intravenous supply of amino acids to patients with moderately increased requirement who are unable to receive sufficient amounts of protein enterally

Australija - anglų - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - tryptophan, quantity: 1.9 g/l; arginine, quantity: 11.3 g/l; phenylalanine, quantity: 7.9 g/l; cysteine, quantity: 0.56 g/l; tyrosine, quantity: 0.23 g/l; glycine, quantity: 7.9 g/l; threonine, quantity: 5.6 g/l; methionine, quantity: 5.6 g/l; leucine, quantity: 7.9 g/l; alanine, quantity: 16 g/l; isoleucine, quantity: 5.6 g/l; aspartic acid, quantity: 3.4 g/l; lysine acetate, quantity: 12.7 g/l (equivalent: lysine, qty 9 g/l); serine, quantity: 4.5 g/l; histidine, quantity: 6.8 g/l; proline, quantity: 6.8 - injection, intravenous infusion - excipient ingredients: glacial acetic acid; water for injections - intravenous supply of amino acids specially to patients with highly increased requirement who are unable to receive sufficient amounts of protein enterally. vamin 18 is also indicated where there is a need to control the total amount of fluid being given to a patient.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - cysteine, quantity: 0.42 g/l; leucine, quantity: 5.9 g/l; tryptophan, quantity: 1.4 g/l; isoleucine, quantity: 4.2 g/l; alanine, quantity: 12 g/l; tyrosine, quantity: 0.17 g/l; histidine, quantity: 5.1 g/l; serine, quantity: 3.4 g/l; lysine acetate, quantity: 9.5 g/l (equivalent: lysine, qty 6.8 g/l); aspartic acid, quantity: 2.5 g/l; valine, quantity: 5.5 g/l; phenylalanine, quantity: 5.9 g/l; glycine, quantity: 5.9 g/l; methionine, quantity: 4.2 g/l; arginine, quantity: 8.4 g/l; threonine, quantity: 4.2 g - injection, intravenous infusion - excipient ingredients: water for injections; glacial acetic acid - intravenous supply of amino acids to patients with moderately increased requirement who are unable to receive sufficient amounts of protein enterally

Australija - anglų - Department of Health (Therapeutic Goods Administration)

a menarini australia pty ltd - nitisinone, quantity: 4 mg - oral liquid, suspension - excipient ingredients: hypromellose; glycerol; polysorbate 80; sodium benzoate; citric acid monohydrate; sodium citrate; purified water; flavour - orfadin (nitisinone) is indicated for the treatment of patients with hereditary tyrosinaemia type 1 in combination with dietary restriction of tyrosine and phenylalanine.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

a menarini australia pty ltd - nitisinone, quantity: 20 mg - capsule, hard - excipient ingredients: pregelatinised maize starch; titanium dioxide; gelatin; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; ethanol absolute; iron oxide black; potassium hydroxide - orfadin (nitisinone) is indicated for the treatment of patients with hereditary tyrosinaemia type 1 in combination with dietary restriction of tyrosine and phenylalanine.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

orpharma pty ltd - nitisinone, quantity: 5 mg - tablet - excipient ingredients: lactose monohydrate; glycerol dibehenate - nityr tablets (nitisinone) are indicated for the treatment of patients with hereditary tyrosinaemia type 1 in combination with dietary restriction of tyrosine and phenylalanine.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

orpharma pty ltd - nitisinone, quantity: 2 mg - tablet - excipient ingredients: lactose monohydrate; glycerol dibehenate - nityr tablets (nitisinone) are indicated for the treatment of patients with hereditary tyrosinaemia type 1 in combination with dietary restriction of tyrosine and phenylalanine.